Newly Published Study Validates How Trina Health Artificial Pancreas Treatment Can Reduce Hospitalization Rates/Costs And Reverse Neuropathy
Published: Jul 26, 2017
SAN CLEMENTE, Calif. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--Animo Health, Inc. dba Trina Health Midwest announced today that its Trina Health Artificial Pancreas Treatment (APT) “represents a new advance to the treatment of diabetes, due to its ability to closely replicate normal pancreatic function,” as reported in a just-published study in The Journal of Diabetes, Metabolic Disorders & Control entitled ‘Microburst Insulin Infusion: Results of Observational Studies—Carbohydrate Metabolism, Painful Diabetic neuropathy, and Hospital/Emergency Department Utilization” (Volume 4 Issue 4 2017).
The study is based on data from three observational retrospective studies that underscore the effectiveness of microburst insulin infusion.
“The Microburst Insulin Infusion Study provides a scientific validation to what we see every day in our clinics,” said Mark Pound, president and CEO of Animo Health, Inc. dba Trina Health Midwest. “After several treatments we’ve seen the Artificial Pancreas Treatment slow, stop and even reverse complications associated with Type 1 and Type 2 diabetes. Patients suffering from neuropathy can feel their feet again and become active again. Patients who were constantly fatigued now have new energy. Patients suffering from retinopathy have improved eyesight. Patients nearing dialysis treatment have been told it’s no longer needed.”
“The Artificial Pancreas Treatment is NOT a cure,” Pound emphasized. “However, it is exponentially improving our patients’ quality of life.”
The Artificial Pancreas Treatment, which more closely mimics the natural burst insulin secretion of a healthy pancreas, showed significant improvement in three observational retrospective studies: carbohydrate metabolism, painful diabetic neuropathy (PDN), and hospital/emergency department utilization.
Carbohydrate metabolism study
These results suggest that the Artificial Pancreas Treatment has a dramatic effect on carbohydrate metabolism; this is of particular importance as the inability to properly metabolize carbohydrates represents a core dysfunction in diabetes.
Painful Diabetic Neuropathy (PDN) study
Among 412 patients studied (80 percent Type 2, 20 percent Type 1) over a three month period, the Artificial Pancreas Treatment completely eliminated or significantly reduced pain in 93 percent of PDN patients.
Hospital and emergency room utilization study
The Artificial Pancreas Treatment dramatically lowers hospital utilization and hospital costs. A two-year retrospective study of 1,524 Type 1 and Type 2 diabetes patients with two or more complications was conducted at 14 centers. The Artificial Pancreas Treatment® (APT) significantly reduced the number of hospital and emergency visits. According to Matched National Hospital Discharge Survey (NHDS) and U.S. Agency for Healthcare Statistics, expected hospitalization rate is 94 per 1,000 patients over a two-year period. The APTs rate is 5. What’s more, expected emergency room visits are 116 per 1,000 patients over two years. The APT rate is 7.
The study stated: “In summary, conventional insulin therapy has achieved only partial success in the treatment of diabetes and prevention of chronic complications…. Microburst insulin therapy represents a new advance in the treatment of diabetes, due to its ability to closely replicate normal pancreatic function. Taken together, the rather dramatic reductions in neuropathic complications and hospital/emergency department visits, as well as the significant improvements in carbohydrate metabolism in these observational studies, may be due to the more precise mimicking of naturally pulsed insulin.”
A PDF Abstract of “Microburst Insulin Infusion: Results of Observational Studies—Carbohydrate Metabolism, Painful Diabetic Neuropathy, and Hospital/Emergency Department Utilization” can be downloaded at http://medcraveonline.com/JDMDC/JDMDC-04-00118.pdf.
About Trina Health LLC, in Partnership with Animo Health, Inc. dba Trina Health Midwest
With over 200,000 treatments with no adverse reactions and more than 24 domestic and international clinics, the Trina Health Artificial Pancreas Treatment is expanding throughout the United States and abroad. Animo Health, Inc., doing business as Trina Health Midwest, has obtained exclusive rights to establish clinics throughout Missouri and the Midwest using Trina Health’s Artificial Pancreas Treatment that can slow, halt, and/or reverse in most cases the chronic complications in Type 1 and Type 2 diabetes. Visit www.trinahealthmidwest.com for more information.
Daly-Swartz PR for Animo Health/Trina Health Midwest
Jeffrey Swartz, 949.470.0075